Service Corporation International is the largest provider of deathcare services in North America, operating approximately 1,800 funeral homes and 500 cemeteries across the United States and Canada under iconic brands including Dignity Memorial, National Cremation Society, and Funeraria del Angel. Founded in 1962 by Robert Waltrip in Houston, Texas, SCI pioneered the "cluster strategy" — acquiring funeral homes and cemeteries in geographic proximity to share management overhead, refrigeration, vehicles, and staff, creating a scalable, durable competitive moat.

SCI's core competitive advantage is its preneed funeral and cemetery contract backlog, which stood at approximately $16.8 billion as of FY2025. These contracts — sold to customers who pre-arrange their own services — represent legally locked-in future revenue. Once a preneed contract is signed, SCI holds the funds (invested in a trust) until the service is performed. This creates a flywheel: every year, the preneed backlog converts to "atneed" (at-time-of-death) revenue, generating predictable, recession-resistant cash flows regardless of economic conditions.

SCI's scale (~16% of the fragmented U.S. death care market) provides structural advantages that smaller independents cannot replicate: national marketing reach, centralized IT/logistics, pricing analytics, and access to capital markets. The business is secular — demand is literally driven by mortality rates, which are improving for SCI as the 76 million Boomer generation ages into peak mortality years (2028–2040 demographic wave). Management estimates this will add 200,000–250,000 incremental deaths per year through 2030, roughly a 6-8% demand uplift.

Green = >10% above current price. Red = >10% below. Gold = within ±10%.

Log-linear trend fitted to full price history. ±1.5σ bands. Green shaded zone = bottom 25% of historical range — historically attractive entry.

Bull Case — What Has to Be True:
The secular demographic thesis is the core: 76 million Boomers aging into peak mortality (2028–2040) represents a structural demand tailwind no competitor can replicate. SCI's $16.8B preneed backlog grows ~5-7% annually and provides locked-in revenue visibility that no other service business can claim. Pricing power in death care is real and durable — SCI raises prices 4-6% annually and customers don't comparison-shop (one of the few industries where price elasticity of demand is near zero). The bull case IV of $128 requires sustained 10% FCF growth over 5 years — achievable if: (a) the Boomer mortality wave arrives on schedule, (b) cremation revenue per call continues rising (families are choosing higher-value memorial packages alongside cremation), and (c) M&A activity in the fragmented ~$20B US market accelerates at attractive multiples.

Base Case — Consensus Delivered:
At 7% near-term FCF growth (roughly tracking analyst EPS consensus of ~11% with capex drag), base intrinsic value is $90. SCI at $79.65 represents an 11.3% discount to base IV — the stock is modestly undervalued relative to fundamental worth. Revenue grows ~4%, consistent with demographics + pricing, with operating leverage expanding EBITDA margins modestly from 30.8% toward 32-33%. Management's FY2026 EPS guidance of $4.00–4.30 implies continued execution. 12-year dividend growth streak continues at 8%/year.

Bear Case — Real Risks:
The bear case (IV $62) requires meaningful deterioration: (1) cremation mix shift accelerating faster than expected with lower average revenue per call (cremation is ~$3,000 vs traditional burial ~$9,000), (2) inability to raise prices above inflation due to competitive pressures from online funeral planners, (3) rising interest expense on the $5.1B debt load crimping free cash flow — the debt is manageable (~5× EBITDA) but leaves little margin for error if rates stay elevated, (4) cemetery land bank becomes constrained in high-density urban markets. None of these risks are imminent, but collectively they define the downside scenario.

Analyst Consensus — Strong Buy:
All 4 analysts rate SCI Buy or Strong Buy with an average PT of $96.50 and JP Morgan's recent initiation at $110 (January 2026). The stock's current -17.3% discount to analyst PT average suggests the street sees meaningful upside that is not priced in. The post-pandemic "normalization" of death rates (elevated COVID-era deaths are past) removes an artificial earnings headwind — FY2025 marks the first clean post-COVID comparison year, and the business still grew revenue 2.9% and EPS 7.6%. The growth cycle is just beginning.